Showing 8561-8570 of 18587 results for "".
- Chronic Steroid Use Could Raise Diabetes Riskhttps://reachmd.com/news/chronic-steroid-use-could-raise-diabetes-risk/2468139/by Dennis Thompson Taking steroids more than doubles a person's risk of
- Op-Ed: Sports Are Fun, Health and Fitness Are Important; Set Your Goals Then Make Them Prioritieshttps://reachmd.com/news/op-ed-sports-are-fun-health-and-fitness-are-important-set-your-goals-then-make-them-priorities/2456719/The winter holiday season is my favorite time of the year. I think many people would agree with me on this statement. However, my reasons for loving this time of year may differ slightly from most. I love the holiday cheer, the time with family, and the kindness that seems to come with
- Bridging the Gap: Managing Cardiovascular Risk in Women with Hypertensive Pregnancy Disorders and Gestational Diabeteshttps://reachmd.com/news/cardiovascular-risks-management-in-women-with-hypertensive-disorders-of-pregnancy-and-gestational-diabetes/2474214/New research is reinforcing what clinicians have long suspected. Pregnancy complications like hypertensive disorders and gestational diabetes are more than transient concerns—they’re early harbingers of long-term cardiovascular disease. Women who experience these c
- Older Adults with Diabetes Faced Elevated Risk of Depression During the COVID-19 Pandemichttps://reachmd.com/news/older-adults-with-diabetes-faced-elevated-risk-of-depression-during-the-covid-19-pandemic/2467643/A recent study of more than 2,700 older Canadians reported older adults with diabetes faced a heightened risk of depression during the COVID-19 pandemic. In this cohort, almost 50% of those who had a pre-pandemic history of depression experienced
- GLP-1 Receptor Agonists: Bridging Metabolic Control and Cardiovascular Protectionhttps://reachmd.com/news/glp-1-receptor-agonists-bridging-metabolic-control-and-cardiovascular-protection/2475771/The expanding use of GLP-1 receptor agonists such as Ozempic is challenging the traditional divide between metabolic control and cardiovascular protection, unveiling underrecognized potential for stroke prevention in patients with type 2 diabetes. The utilization of
- Weight Loss and Glucose Management: Transitioning from Old to New Medicationshttps://reachmd.com/news/weight-loss-and-glucose-management-transitioning-from-old-to-new-medications/2474175/Emerging research affirms that next-generation weight loss and glucose management medications are transforming treatment outcomes for patients with type 2 diabetes, offering superior efficacy and potential economic savings. The advent of these c
- Therapeutic Plasma Exchange and Biological Aging: A New Hope in Geriatricshttps://reachmd.com/news/therapeutic-plasma-exchange-and-biological-aging-a-new-hope-in-geriatrics/2474990/Clinicians have long sought interventions capable of reversing biological aging and improving patient resilience, and now a
- Compound from Olives Shows Promise for Treating Obesity and Diabetes, Claims Studyhttps://reachmd.com/news/compound-from-olives-shows-promise-for-treating-obesity-and-diabetes-claims-study/2467587/Chicago: Findings from a new mouse study suggest that elenolic acid, a natural compound found in olives, can lower blood sugar levels and promote weight loss.The research could pave the way to the development of safe and inexpensive natural products for managing
- Study Reveals Avocado May Lower Diabetes Risk in Women, Not Menhttps://reachmd.com/news/study-reveals-avocado-may-lower-diabetes-risk-in-women-not-men/2463092/In a recent cross-sectional study published in the Journal of the Academy of Nutrition and Dietetics, researchers from Mexico investigat
- New Study Focuses on the Placenta for Clues to the Development of Gestational Diabeteshttps://reachmd.com/news/new-study-focuses-on-the-placenta-for-clues-to-the-development-of-gestational-diabetes/2462758/Marie-France Hivert, MD, MMSc BOSTON, MA – A new study led by the Harvard Pilgrim Health Care Institute has identified that a deficit in the placental expression of the gene insulin-like growth factor 1 (IGFBP1) and low IGFBP